SOUTH SAN FRANCISCO, Calif. — August 13, 2025 — Leads & Copy — Aligos Therapeutics, Inc. (Nasdaq: ALGS) has begun dosing patients in the Phase 2 B-SUPREME study of its investigational compound ALG-000184 for chronic hepatitis B virus (HBV) infection. The study aims to evaluate the safety and efficacy of ALG-000184 monotherapy compared with tenofovir disoproxil fumarate in approximately 200 adult subjects with chronic HBV infection over 48 weeks.
Dr. Nezam Afdhal from Beth Israel Deaconess Medical Center expressed optimism about the potential of therapies like ALG-000184, citing the impressive antiviral activity observed in clinical trials. Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer at Aligos Therapeutics, highlighted the significance of this milestone and the potential of ALG-000184 as a first/best-in-class treatment.
ALG-000184, an oral small molecule capsid assembly modulator, has shown promising results in Phase 1 studies, demonstrating tolerability, linear pharmacokinetics, and antiviral activity. Interim data from the Phase 2 B-SUPREME study is projected in 2026, with topline data anticipated in 2027.
Chronic HBV infection affects 254 million patients worldwide and leads to complications, including cirrhosis and liver cancer. Aligos Therapeutics is dedicated to developing best-in-class therapies for liver and viral diseases.
Contact:
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
+1 (650) 910-0427
jtarazi@aligos.com
Media Contact:
Jake Robison
Vice President, Inizio Evoke
Jake.Robison@inzioevoke.com
Source: Aligos Therapeutics, Inc.
